Cocrystal Pharma (NASDAQ:COCP) Stock Price Down 1.9% – Should You Sell?

Cocrystal Pharma, Inc. (NASDAQ:COCP)’s stock price traded down 1.9% on Friday . The company traded as low as $1.0304 and last traded at $1.04. 13,569 shares were traded during trading, a decline of 86% from the average session volume of 99,907 shares. The stock had previously closed at $1.06.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Cocrystal Pharma in a research note on Monday, December 22nd. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, Cocrystal Pharma presently has a consensus rating of “Hold” and an average price target of $6.00.

Cocrystal Pharma Price Performance

The business’s fifty day moving average price is $1.03 and its 200-day moving average price is $1.27. The stock has a market capitalization of $14.33 million, a PE ratio of -1.11 and a beta of 1.13.

Cocrystal Pharma (NASDAQ:COCP) last posted its earnings results on Friday, November 14th. The company reported ($0.19) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.03. On average, analysts expect that Cocrystal Pharma, Inc. will post -1.85 earnings per share for the current fiscal year.

Insider Transactions at Cocrystal Pharma

In other Cocrystal Pharma news, Director Phillip Md Et Al Frost bought 50,000 shares of Cocrystal Pharma stock in a transaction that occurred on Wednesday, December 31st. The stock was acquired at an average cost of $0.95 per share, for a total transaction of $47,500.00. Following the completion of the transaction, the director directly owned 1,838,551 shares in the company, valued at $1,746,623.45. This represents a 2.80% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Insiders acquired a total of 159,000 shares of company stock worth $152,710 over the last three months. 28.14% of the stock is currently owned by company insiders.

About Cocrystal Pharma

Cocrystal Pharma, Inc (NASDAQ:COCP) is a clinical-stage biotechnology company focused on the discovery and development of novel antiviral therapeutics. Utilizing an integrated structure-guided drug design platform, the company combines x-ray crystallography, computational chemistry and medicinal chemistry to identify and optimize small molecule inhibitors targeting key viral enzymes. This approach is intended to accelerate the progression of lead candidates from discovery through preclinical development.

The company’s pipeline includes multiple preclinical programs aimed at treating respiratory and systemic viral infections.